Papatheodoridis,, G. V. Et Al. 2016. The risk of hepatocellular carcinoma HCC is decreasingafter the first 5 years of entecavir ETV or tenofovir TDF therapy in Caucasian chronic hepatitis B CHB patients. AASLD 2016 .

Papatheodoridis,, G. V., YURTAYDIN, S. C., Dalekos, G. N., Buti, M., Chi, H., van Bömmel, F., ... Calleja, J. L.(2016). The risk of hepatocellular carcinoma HCC is decreasingafter the first 5 years of entecavir ETV or tenofovir TDF therapy in Caucasian chronic hepatitis B CHB patients . AASLD 2016

Papatheodoridis,, ONUR Et Al. "The risk of hepatocellular carcinoma HCC is decreasingafter the first 5 years of entecavir ETV or tenofovir TDF therapy in Caucasian chronic hepatitis B CHB patients," AASLD 2016, 2016

Papatheodoridis,, ONUR Et Al. "The risk of hepatocellular carcinoma HCC is decreasingafter the first 5 years of entecavir ETV or tenofovir TDF therapy in Caucasian chronic hepatitis B CHB patients." AASLD 2016 , 2016

Papatheodoridis,, G. V. Et Al. (2016) . "The risk of hepatocellular carcinoma HCC is decreasingafter the first 5 years of entecavir ETV or tenofovir TDF therapy in Caucasian chronic hepatitis B CHB patients." AASLD 2016 .

@conferencepaper{conferencepaper, author={ONUR KESKİN Et Al. }, title={The risk of hepatocellular carcinoma HCC is decreasingafter the first 5 years of entecavir ETV or tenofovir TDF therapy in Caucasian chronic hepatitis B CHB patients}, congress name={AASLD 2016}, city={}, country={}, year={2016}}